It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive ...
The Chosun Ilbo on MSN
Oral obesity drugs near FDA approval, domestic launch planned
New obesity treatments such as 'oral Mounjaro' and 'high-dose Wegovy' are scheduled to be released next year. The U.S. Food ...
A wave of transformative US drug-pricing agreements and record manufacturing investments from leading biopharmaceutical ...
Very few investors can match Stanley Druckenmiller. He delivered an average annual return of over 30% over three decades at ...
The Huntsville Planning Commission voted to rezone 73.40 acres east of Greenbrier Road and north of Interstate 565 in ...
As physicians across specialties encounter increasing patient interest in GLP-1 receptor agonists, it is important for them ...
No increased risk for cancer was found among patients with RA receiving biologic or targeted synthetic DMARDs vs TNF inhibitors.
Combining elacestrant with targeted agents produced “clinically meaningful” outcomes for patients with locally advanced or metastatic ER-positive/HER2-negative breast cancer who have received at least ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results